
A drug laboratory in WEDZ. [Photo/WeChat account: whkfq]
Wuhan Economic & Technological Development Zone (WEDZ) is utilizing a "lease-to-equity" model to transform an old warehouse into a state-of-the-art cell and gene therapy (CGT) pilot platform, aiming to accelerate the transition of innovative drugs from research to clinical trials.
The pilot platform will focus on small-batch production, advancing pharmaceutical R&D clients through clinical phases I and II, and providing essential testing services for enterprises in the zone.
The "lease-to-equity" model is central to this effort, engaging core technology teams and encouraging participation from industry-leading companies.
WEDZ launched the first phase of the CGT pilot platform in its biopharmaceutical innovation park earlier this year, enabling product transformation for universities and research institutions in Beijing, Fujian, Hangzhou, and beyond.
CGT is a focal point of WEDZ's recent efforts to develop its health and biotechnology industries, with the zone having attracted top-tier medical institutions and over 100 health enterprises, including Tongji Hospital and Wuhan University People's Hospital.
WEDZ offers space and facilities, supporting the platform's technological achievements and project implementation. Meanwhile, Brain Case, a drug developer in the zone, contributes its talent and expertise for pipeline development and project incubation.
The CGT pilot platform has optimized operations and established collaborations with top expert teams from institutions such as Xiangya Second Hospital of Central South University and Tongji Hospital to develop innovative drugs.